Brief: IP Group Says Pulmocide Terminates Opera-T Phase 3 Study With Opelconazole
07/01/2026 14:19
Jan 7 (Reuters) - IP Group PLC IPO.L: IP GROUP PLC - PULMOCIDE ANNOUNCES TERMINATION OF PHASE 3 STUDY IP GROUP PLC - PULMOCIDE TERMINATES OPERA-T PHASE 3 STUDY WITH OPELCONAZOLE IP GROUP PLC - PULMOCIDE TO REVIEW TRIAL DATA FOR NEXT STEPS IP GROUP PLC - EXPECTS TO REDUCE PULMOCIDE ASSET VALUE Source text: ID:nRSG0378Oa Further company coverage: IPO.L ((Reuters.Briefs@thomsonreuters.com;))